六城市医疗机构质子泵抑制剂药物使用分析

Utilization of Proton Pump Inhibitors in Six Areas in China

目的考察2011～2013年北京、成都、广州、上海、天津、杭州六城市医疗机构质子泵抑制剂使用合理性。方法利用EXCEL软件对质子泵抑制剂类药物药占比、用药频度（DDDs）、药品限定日费用（DDDc）、年均增长率（AARG）、药物相互作用、进口/国产及医保用药的情况进行分析。结果质子泵抑制剂总使用量逐年上升,奥美拉唑占优势地位,临床信任度高;雷贝拉唑、兰索拉唑近三年用量增长最快,国产药品增长多于进口药品,医保类别对临床用药影响不大;同时,质子泵抑制剂的价格逐渐走低;在联合用药情况下临床倾向于选择安全性较高的雷贝拉唑、泮托拉唑,有临床药师干预时质子泵抑制剂的使用更为合理。结论质子泵抑制剂药物总体使用情况趋于更加合理,且专科临床药师的工作非常有利于促进用药合理化。

OBJECTIVE To investigate the rationality and trend of utilization of proton pump inhibitors （PPIs） in six areas in China in 2011 - 2013. METHODS The utilization of PPIs in Beijing, Chengdu, Guangzhou, Shanghai, Tianjin, and Hangzhon dur- ing the period of 2011 -2013 were analyzed statistically in respect of consumption sum, DDDs, AARG, DDC, drug interactions, and medical insurance categary. RESULTS Both the consumption sum and DDDs of PPIs increased quickly in the recent three years. The amount of omeprazole was the greatest and increased steadily. The amounts of rabeprazole and lansoprazole also increased rapidly especially for the domestic products. Medical insurance categary had no obvious effect on clinical choice. PPIs became more cheaper for patients. Rabeprazole and pantoprazole were preferred when PPIs were combined with other drugs, especially in the hospitals which had clinical pharmacist working in the department of gastroenterology or cardiology. CONCLUSION The use of PPIs tends to be more rational, in which clinical pharmacists play a very important role.